Achilles Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Achilles Therapeutics CEO'su Iraj Ali, Jan2018 tarihinde atandı, in görev süresi 6.83 yıldır. in toplam yıllık tazminatı $ 1.70M olup, şirket hissesi ve opsiyonları dahil olmak üzere 27.3% maaş ve 72.7% ikramiyelerden oluşmaktadır. şirketin hisselerinin 2.71% ine doğrudan sahiptir ve bu hisseler $ 1.15M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.4 yıl ve 4.5 yıldır.

Anahtar bilgiler

Iraj Ali

İcra Kurulu Başkanı

US$1.7m

Toplam tazminat

CEO maaş yüzdesi	27.3%
CEO görev süresi	6.8yrs
CEO sahipliği	2.7%
Yönetim ortalama görev süresi	5.4yrs
Yönetim Kurulu ortalama görev süresi	4.5yrs

Son yönetim güncellemeleri

Recent updates

Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Invest In Growth?

Sep 20

Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans?

Feb 26

Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Nov 13

Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Jul 19

Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans?

Mar 11

Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Nov 18

Achilles-led group gets €4M funding for personalized cell therapy manufacturing

Jul 21

Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Invest In Growth?

Apr 13

Achilles Therapeutics (NASDAQ:ACHL) Is In A Good Position To Deliver On Growth Plans

Dec 27

Here's Why We're Not Too Worried About Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Sep 09

CEO Tazminat Analizi

Iraj Ali'un ücretlendirmesi Achilles Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$64m
Mar 31 2024	n/a	n/a	-US$64m
Dec 31 2023	US$2m	US$463k	-US$70m

Tazminat ve Piyasa: Iraj 'nin toplam tazminatı ($USD 1.70M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 653.16K ).

Tazminat ve Kazançlar: Iraj şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Iraj Ali (49 yo)

6.8yrs

Görev süresi

US$1,698,000

Tazminat

Dr. Iraj Ali, Ph.D. serves as Chief Executive Officer at Achilles Therapeutics Plc since December 10, 2018 and served as its Interim Chief Executive Officer since January 2018 until December 10, 2018. Dr....

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Iraj Ali	CEO & Director	6.8yrs	US$1.70m	2.71% $ 1.2m
Sergio Quezada	Founder & Chief Scientific Officer	8.8yrs	Veri yok	1.12% $ 478.0k
Robert Coutts	Chief Financial Officer	4yrs	Veri yok	0.66% $ 279.0k
Mark Lowdell	Founder & Member of Scientific Advisory Board	8.8yrs	Veri yok	Veri yok
Charles Swanton	Founder & Member of Scientific Advisory Board	8.8yrs	Veri yok	Veri yok
Lee Stern	Vice President of Investor Relations & External Communications	3.9yrs	Veri yok	Veri yok
Daniel Carey Hood	General Counsel & Company Secretary	2yrs	Veri yok	Veri yok
Julia Wilson	Head of Communications	no data	Veri yok	Veri yok
Tariq Ahmed	Executive Vice President of People	no data	Veri yok	Veri yok
Edward Samuel	Executive Vice President of Technical Operations	no data	Veri yok	Veri yok
Shree Patel	Executive Vice President of Supply Operations	no data	Veri yok	Veri yok
James A. Taylor	Chief Business Officer	2.8yrs	Veri yok	Veri yok

5.4yrs

Ortalama Görev Süresi

50.5yo

Ortalama Yaş

Deneyimli Yönetim: ACHL 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.4 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Iraj Ali	CEO & Director	8.7yrs	US$1.70m	2.71% $ 1.2m
Mark Lowdell	Founder & Member of Scientific Advisory Board	less than a year	Veri yok	Veri yok
Charles Swanton	Founder & Member of Scientific Advisory Board	less than a year	Veri yok	Veri yok
Edwin Moses	Independent Chairman of the Board	5.9yrs	US$379.00k	0.55% $ 234.2k
Carsten Boess	Independent Non-Executive Director	4.6yrs	US$176.00k	0% $ 0
Markwin Velders	Member of Scientific Advisory Board	3.5yrs	Veri yok	Veri yok
Scott Antonia	Member of Scientific Advisory Board	4.5yrs	Veri yok	Veri yok
Michael Giordano	Independent Non-Executive Director	6.2yrs	US$189.00k	0.11% $ 48.3k
Karl Peggs	Founder & Member of Scientific Advisory Board	less than a year	Veri yok	1.36% $ 579.7k
Elizabeth Jaffee	Member of Scientific Advisory Board	4.5yrs	Veri yok	Veri yok
Christopher Klebanoff	Member of Scientific Advisory Board	4.5yrs	Veri yok	Veri yok
Alena Gros	Member of Scientific Advisory Board	2.8yrs	Veri yok	Veri yok

4.5yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ACHL 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.5 yıldır).

Achilles Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

High number of new and inexperienced directors

High number of new and inexperienced directors

Achilles Therapeutics plc Announces Management Appointments, Effective July 1, 2022

Achilles Therapeutics plc, Annual General Meeting, Jun 28, 2022

Achilles Therapeutics plc Announces Management Changes

High number of new and inexperienced directors

Recent updates

Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Invest In Growth?

New minor risk - Share price stability

Price target decreased by 25% to US$4.13

High number of new and inexperienced directors

Achilles Therapeutics plc Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning

New minor risk - Share price stability

Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans?

Price target decreased by 19% to US$6.88

Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Achilles Therapeutics plc Announces New Immunogenicity Prediction Application of its AI-Powered PELEUS Platform Uniquely Identifies Most Potent T Cell Antigens

Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans?

Achilles Therapeutics plc Updates Interim Results from the Ongoing Phase I/IIa Chiron and Thetis Clinical Trials

Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Price target increased to US$12.80

High number of new and inexperienced directors

Achilles-led group gets €4M funding for personalized cell therapy manufacturing

Achilles Therapeutics plc Announces Management Appointments, Effective July 1, 2022

Price target decreased to US$14.40

Achilles Therapeutics plc, Annual General Meeting, Jun 28, 2022

Achilles Therapeutics plc Doses First Patient with Higher-dose cNeT in Phase I/IIa CHIRON Trial in Advanced NSCLC and Initiates Enrollment in Cohort B of the THETIS Trial (cNeT + PD-1 checkpoint inhibitor) in Metastatic Malignant Melanoma

Achilles Therapeutics plc Announces Management Changes

High number of new and inexperienced directors

Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Invest In Growth?

Achilles Therapeutics plc Appoints Alena Gros and Ben Creelan to Its Scientific Advisory Board

Achilles Therapeutics (NASDAQ:ACHL) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Achilles Therapeutics Enrolls First Us Patient in Ongoing Phase I/Iia Study in Advanced Non-Small Cell Lung Cancer

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş